Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor

ACS Combinatorial Science

Volumn 16, Issue 8, 2014, Pages 393-396

  Boltjes, André ^a   Huang, Yijun ^b   Van De Velde, Rob ^a   Rijkee, Laurie ^a   Wolf, Siglinde ^c   Gaugler, James ^b   Lesniak, Katarzyna ^d   Guzik, Katarzyna ^d   Holak, Tad A ^c,d   Dömling, Alexander ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

library generation; peptidomimetic p53 Mdm4 inhibitor; Ugi four component reaction

Indexed keywords

LIGAND; MDM2 PROTEIN, HUMAN; PEPTIDOMIMETIC AGENT; PROTEIN MDM2; PROTEIN P53;

ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; PROTEIN PROTEIN INTERACTION;

DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PEPTIDOMIMETICS; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905823366     PISSN: 21568952     EISSN: None     Source Type: Journal    
DOI: 10.1021/co500026b     Document Type: Article

References (24)

1. Cheok, C. F.; Verma, C. S.; Baselga, J.; Lane, D. P. Translating p53 into the clinic Nat. Rev. Clin Oncol 2011, 8, 568-568
2. Khoury, K.; Popowicz, G. M.; Holak, T. A.; Dömling, A. The p53-MDM2/MDMX axis -A chemotype perspective MedChemComm 2011, 2, 246-260
3. Popowicz, G. M.; Dömling, A.; Holak, T. A. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious Angew. Chem., Int. Ed. 2011, 50, 2680-2688
4. Carry, J. C.; Garcia-Echeverria, C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic Bioorg. Med. Chem. Lett. 2013, 23, 2480-5
5. Popowicz, G. M.; Czarna, A.; Rothweiler, U.; Szwagierczak, A.; Krajewski, M.; Weber, L.; Holak, T. A. Molecular basis for the inhibition of p53 by Mdmx Cell Cycle 2007, 6, 2386-2392
6. Berghausen, J.; Buschmann, N.; Furet, P.; Gessier, F.; Hergovich, L. J.; Holzer, P.; Jacoby, E.; Kallen, J.; Masuya, K.; Pissot, S. C.; Ren, H.; Stutz, S. Isoquinolinone and quinazolinone derivatives as MDM2 and MDM4 inhibitors and their preparation and use for the treatment of diseases. Int. Patent WO2011076786A1.
7. Bold, G.; Furet, P.; Gessier, F.; Kallen, J.; Hergovich, L. J.; Masuya, K.; Vaupel, A. Preparation of tetrasubstituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators. Int. Patent WO2011023677A1.
8. Reed, D.; Shen, Y.; Shelat, A. A.; Arnold, L. A.; Ferreira, A. M.; Zhu, F.; Mills, N.; Smithson, D. C.; Regni, C. A.; Bashford, D.; Cicero, S. A.; Schulman, B. A.; Jochemsen, A. G.; Guy, R. K.; Dyer, M. A. Identification and characterization of the first small molecule inhibitor of MDMX J. Biol. Chem. 2010, 285, 10786-10796
9. Lee, J. H.; Zhang, Q.; Jo, S.; Chai, S. C.; Oh, M.; Im, W.; Lu, H.; Lim, H.-S. Novel pyrrolopyrimidine-based -helix mimetics: Cell-permeable inhibitors of protein-protein interactions J. Am. Chem. Soc. 2010, 133, 676-679
10. Marine, J.-C. W.; Dyer, M. A.; Jochemsen, A. G. MDMX: From bench to bedside J. Cell Sci. 2007, 120, 371-378
11. Srivastava, S.; Beck, B.; Wang, W.; Czarna, A.; Holak, T. A.; Dömling, A. Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists J. Comb. Chem. 2009, 11, 631-639
12. Popowicz, G. M.; Czarna, A.; Wolf, S.; Wang, K.; Wang, W.; Dömling, A.; Holak, T. A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 2010, 9, 1104-1111
13. Huang, Y.; Wolf, S.; Bista, M.; Meireles, L.; Camacho, C.; Holak, T. A.; Dömling, A. 1,4-Thienodiazepine-2,5-diones via MCR (I): Synthesis, virtual space and p53-Mdm2 activity Chem. Biol. Drug Des. 2010, 76, 116-129
14. Czarna, A.; Beck, B.; Srivastava, S.; Popowicz, G. M.; Wolf, S.; Huang, Y.; Bista, M.; Holak, T. A.; Dömling, A. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists Angew. Chem., Int. Ed. 2010, 49, 5352-5356
15. Bista, M.; Kowalska, K.; Janczyk, W.; Dömling, A.; Holak, T. A. Robust NMR screening for lead compounds using tryptophan-containing proteins J. Am. Chem. Soc. 2009, 131, 7500-7501
16. Rothweiler, U.; Czarna, A.; Krajewski, M.; Ciombor, J.; Kalinski, C.; Khazak, V.; Ross, G.; Skobeleva, N.; Weber, L.; Holak, T. A. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction ChemMedChem. 2008, 3, 1118-1128
17. Popowicz, G.; Czarna, A.; Holak, T. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Cell Cycle 2008, 7, 2441-2443
18. Rothweiler, U.; Czarna, A.; Weber, L.; Popowicz, G. M.; Brongel, K.; Kowalska, K.; Orth, M.; Stemmann, O.; Holak, T. A. NMR screening for lead compounds using tryptophan-mutated proteins J. Med. Chem. 2008, 51, 5035-5042
19. Czarna, A.; Popowicz, G. M.; Pecak, A.; Wolf, S.; Dubin, G.; Holak, T. A. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx Cell Cycle 2009, 8, 1176-1184
20. Huang, Y.; Wolf, S.; Koes, D.; Popowicz, G. M.; Camacho, C. J.; Holak, T. A.; Dömling, A. Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists ChemMedChem. 2012, 7, 49-52
21. Koes, D.; Khoury, K.; Huang, Y.; Wang, W.; Bista, M.; Popowicz, G. M.; Wolf, S.; Holak, T. A.; Dömling, A.; Camacho, C. J. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists PLoS One 2012, 7 (3 e32839
22. Huang, Y.; Wolf, S.; Beck, B.; Köhler, L. M.; Khoury, K.; Popowicz, G. M.; Goda, S. K.; Subklewe, M.; Twarda, A.; Holak, T. A.; Dömling, A. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities Chem. Biol. 2014, 9, 802-11
23. Bista, M.; Wolf, S.; Khoury, K.; Kowalska, K.; Huang, Y.; Wrona, E.; Arciniega, M.; Popowicz, G. M.; Holak, T. A.; Dömling, A. Transient protein states in designing inhibitors of the MDM2-p53 interaction Structure 2014, 21, 2143-51
24. Cao, H.; Liu, H.; Dömling, A. Efficient multicomponent reaction synthesis of the schistosomiasis drug praziquantel Chem.-Eur. J. 2010, 16, 12296-8